Tags

Type your tag names separated by a space and hit enter

An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV.
J Eur Acad Dermatol Venereol. 2007 May; 21(5):596-601.JE

Abstract

BACKGROUND

Seborrhoeic dermatitis (SD) is a common dermatosis in human immunodeficiency virus (HIV)-positive patients, many of whom do not respond satisfactorily to conventional topical treatments such as corticosteroids and antifungals.

OBJECTIVE

A pilot study to investigate the efficacy and tolerability of pimecrolimus cream 1% in HIV-positive patients with facial SD.

METHODS

In a single-centre study, 21 HIV-infected patients with mild to severe SD were treated twice daily with pimecrolimus cream 1% for 14 days. Thereafter, treatment was discontinued and patients followed up for 5 weeks. Skin involvement at baseline and on days 7, 14, 21, 35 and 49 was assessed using a four-point clinical score and digital photography.

MAIN OUTCOME MEASURES

Efficacy and safety of pimecrolimus cream 1% treatment and incidence of relapse in the follow-up phase. Results Marked improvement was seen in clinical parameters at day 7, with >or= 90% patients clear of symptoms at day 14. Relapse was observed at day 35 but signs were milder than at baseline. All patients responded to therapy, despite their immunological status. Pimecrolimus did not alter CD4(+) and CD8(+) T-cell counts or viral load during the treatment period.

CONCLUSION

Pimecrolimus cream represents a new, effective therapeutic option for facial SD in HIV patients.

Links

Aggregator Full Text

Authors+Show Affiliations

de Moraes AP
São José Hospital of Infectious Diseases, Ceará, Brazil. andypmoraes@yahoo.com.br
de Arruda EA
No affiliation info available
Vitoriano MA
No affiliation info available
de Moraes Filho MO
No affiliation info available
Bezerra FA
No affiliation info available
de Magalhães Holanda E
No affiliation info available
de Moraes ME
No affiliation info available

MeSH

Administration, TopicalAdultDermatitis, SeborrheicDermatologic AgentsFacial DermatosesFemaleHIV InfectionsHumansMaleMiddle AgedOintmentsPilot ProjectsRecurrenceTacrolimusTreatment Outcome

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17447972

Citation

de Moraes, A P., et al. "An Open-label Efficacy Pilot Study With Pimecrolimus Cream 1% in Adults With Facial Seborrhoeic Dermatitis Infected With HIV." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 21, no. 5, 2007, pp. 596-601.
de Moraes AP, de Arruda EA, Vitoriano MA, et al. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. J Eur Acad Dermatol Venereol. 2007;21(5):596-601.
de Moraes, A. P., de Arruda, E. A., Vitoriano, M. A., de Moraes Filho, M. O., Bezerra, F. A., de Magalhães Holanda, E., & de Moraes, M. E. (2007). An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. Journal of the European Academy of Dermatology and Venereology : JEADV, 21(5), 596-601.
de Moraes AP, et al. An Open-label Efficacy Pilot Study With Pimecrolimus Cream 1% in Adults With Facial Seborrhoeic Dermatitis Infected With HIV. J Eur Acad Dermatol Venereol. 2007;21(5):596-601. PubMed PMID: 17447972.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV. AU - de Moraes,A P, AU - de Arruda,E A G, AU - Vitoriano,M A V, AU - de Moraes Filho,M O, AU - Bezerra,F A F, AU - de Magalhães Holanda,E, AU - de Moraes,M E A, PY - 2007/4/24/pubmed PY - 2007/6/29/medline PY - 2007/4/24/entrez SP - 596 EP - 601 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 21 IS - 5 N2 - BACKGROUND: Seborrhoeic dermatitis (SD) is a common dermatosis in human immunodeficiency virus (HIV)-positive patients, many of whom do not respond satisfactorily to conventional topical treatments such as corticosteroids and antifungals. OBJECTIVE: A pilot study to investigate the efficacy and tolerability of pimecrolimus cream 1% in HIV-positive patients with facial SD. METHODS: In a single-centre study, 21 HIV-infected patients with mild to severe SD were treated twice daily with pimecrolimus cream 1% for 14 days. Thereafter, treatment was discontinued and patients followed up for 5 weeks. Skin involvement at baseline and on days 7, 14, 21, 35 and 49 was assessed using a four-point clinical score and digital photography. MAIN OUTCOME MEASURES: Efficacy and safety of pimecrolimus cream 1% treatment and incidence of relapse in the follow-up phase. Results Marked improvement was seen in clinical parameters at day 7, with >or= 90% patients clear of symptoms at day 14. Relapse was observed at day 35 but signs were milder than at baseline. All patients responded to therapy, despite their immunological status. Pimecrolimus did not alter CD4(+) and CD8(+) T-cell counts or viral load during the treatment period. CONCLUSION: Pimecrolimus cream represents a new, effective therapeutic option for facial SD in HIV patients. SN - 0926-9959 UR - https://www.unboundmedicine.com/medline/citation/17447972/An_open_label_efficacy_pilot_study_with_pimecrolimus_cream_1_in_adults_with_facial_seborrhoeic_dermatitis_infected_with_HIV_ L2 - https://doi.org/10.1111/j.1468-3083.2006.01923.x DB - PRIME DP - Unbound Medicine ER -